Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, are set forth in the tables below:

	As of June 30, 2018				Fair Value Measurements
	Carrying		Fair		As of June 30, 2018
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,427	$	1,427	$	-	$	-	$	1,427
Other long-term liabilities:
Warrant liability ⁽²⁾		407		407		-		-		407
	$	1,834	$	1,834	$	-	$	-	$	1,834

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability ⁽²⁾		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

⁽¹⁾⁽²⁾See Note 7, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:

								Cancellation		Mark to
	December 31,							of Obligation/		Market			June 30,
	2017		Payments			Accretion		Conversions		Adjustment			2018
	(unaudited)

Asuragen	$	1,581	$	(155	)	$	1	$	-	$	-		$	1,427

Underwriters Warrant		473		-					-		(66	)		407
	$	2,054	$	(155	)	$	1	$	-	$	(66	)	$	1,834